Table 3.
Effect of esomeprazole on erlotinib pharmacokinetics
| Pharmacokinetic parameters | No PPI [n = 9] | PPI [n = 9] | RD, PPI vs. no PPI (95% CI) | p value |
|---|---|---|---|---|
| Erlotinib | ||||
| AUC24 (CV %), geomean μg*h/mL | 20.1 (30) | 10.6 (51) | − 47% (− 58 to − 34%) | < 0.001 |
| Cmax (CV %), geomean μg/mL | 1.72 (32) | 0.75 (46) | − 56% (− 64 to − 46%) | < 0.001 |
Pharmacokinetic results for patients who participated in both study arms, corrected for coadministration with milk
AUC24 area under the curve from time zero to 24 h, CI confidence interval. RD relative difference, Cmax maximum concentration, CV coefficient of variation, PPI proton pump inhibitor